Sequana Medical N.V. Stock price

Equities

SEQUA

BE0974340722

Biotechnology & Medical Research

Real-time Euronext Bruxelles 11:57:42 2024-03-28 am EDT 5-day change 1st Jan Change
1.53 EUR -1.92% Intraday chart for Sequana Medical N.V. +5.48% -61.50%
Sales 2023 * 888K 960K Sales 2024 * 653K 706K Capitalization 44.06M 47.61M
Net income 2023 * -31M -33.5M Net income 2024 * -23M -24.86M EV / Sales 2023 * 63 x
Net Debt 2023 * 11.85M 12.81M Net Debt 2024 * 29.45M 31.83M EV / Sales 2024 * 113 x
P/E ratio 2023 *
-1.4 x
P/E ratio 2024 *
-1.55 x
Employees 70
Yield 2023 *
-
Yield 2024 *
-
Free-Float 76.56%
More Fundamentals * Assessed data
Dynamic Chart
Sequana Medical Raises EUR11.5 Million via Share Placement MT
Sequana Medical's Premarket Application for Alfapump Accepted by US FDA; Shares Rise MT
Sequana Medical Receives New US Reimbursement Codes for Alfapump System MT
Belgium's Sequana Medical Seeks US FDA Premarket Approval for Liver Ascites Treatment Device MT
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure CI
Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director CI
Certain Shares of Sequana Medical NV are subject to a Lock-Up Agreement Ending on 22-OCT-2023. CI
Transcript : Sequana Medical NV - Special Call
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome CI
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Sequana Medical NV, H1 2023 Earnings Call, Sep 14, 2023
Belgium’s Sequana Medical Enrolls First Patient in Early-stage Trial for Treatment of Chronic Heart Failure MT
Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure CI
Sequana Medical NV Announces Completion of 1,000th Alfapump Implant CI
Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director CI
More news

Latest transcript on Sequana Medical N.V.

1 day-1.92%
1 week+4.79%
Current month-35.98%
1 month-38.80%
3 months-60.87%
6 months-49.34%
Current year-61.75%
More quotes
1 week
1.37
Extreme 1.365
1.74
1 month
1.36
Extreme 1.36
2.69
Current year
1.36
Extreme 1.36
4.85
1 year
1.36
Extreme 1.36
5.18
3 years
1.36
Extreme 1.36
9.80
5 years
1.36
Extreme 1.36
12.40
10 years
1.36
Extreme 1.36
12.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 15-12-31
Director of Finance/CFO 50 -
Chief Tech/Sci/R&D Officer 56 -
Members of the board TitleAgeSince
Director/Board Member 66 22-07-18
Director/Board Member 68 18-11-07
Director/Board Member - Nov. 09
More insiders
Date Price Change Volume
24-03-28 1.53 -1.92% 376 791
24-03-27 1.56 -3.70% 137,032
24-03-26 1.62 -4.71% 217,348
24-03-25 1.7 +10.03% 516,687
24-03-22 1.545 +5.82% 387,433

Real-time Euronext Bruxelles, March 28, 2024 at 10:58 am EDT

More quotes
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.56 EUR
Average target price
7.633 EUR
Spread / Average Target
+389.32%
Consensus
  1. Stock
  2. Equities
  3. Stock Sequana Medical N.V. - Euronext Bruxelles